News
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Cancellation of remaining publicly held registered shares of Vifor Pharma AG
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma AG ("Vifor") announced today that the Commercial Court St. Gallen has cancelled (kraftlos erklärt) all remaining
Cosmo announces successful Phase III clinical trial of Lumeblue™ in China
LivaNova Announces Receipt of Close-Out of Warning Letter from U.S. Food and Drug Administration
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced it received a close-out letter from the U.S. Food and Drug Administration (FDA) for the
ICON recognised as leading contract research organisation and employer by Scrip, Fierce Life Sciences, Financial Times and others
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been recognised with a number of coveted business and industry awards over the second half
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
QIAGEN receives FDA approval for companion diagnostic to Mirati Therapeutics’ KRAZATI in non-small cell lung cancer
QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) has announced the U.S. Food and Drug Administration (FDA) approval of its therascreen® KRAS RGQ PCR kit (therascreen KRAS kit) as a companion
Therapie für nicht-kleinzelliges Lungenkarzinom: QIAGEN erhält FDA-Zulassung für Begleitdiagnostikum zu KRAZATI von Mirati Therapeutics
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat von der US-amerikanischen Arzneimittelzulassungsbehörde FDA die Zulassung des therascreen® KRAS RGQ PCR-Kits (therascreen KRAS-Kit) als
Xencor Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma at the American Society of Hematology Annual Meeting
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
EQS-News: BB BIOTECH AG: Molecular strike force for the immune system
Acadia Healthcare Provides Business Outlook Ahead of Investor Day
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) will host its first Investor Day beginning at approximately 9:00 a.m. Eastern Time today, Wednesday, December 7, 2022, in New York City.
During the
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Charles River Laboratories Adds Craig B. Thompson, M.D. to Board of Directors
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the re-appointment of Craig B. Thompson, M.D., former President and Chief Executive Officer, Memorial Sloan-Kettering
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Sonova completes acquisition of the HYSOUND Group, expanding direct consumer access in China
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Charles River Launches Endosafe Nexus 200, Emphasizes Critical Importance of Smart Automation for Endotoxin Detection
Charles River Laboratories International, Inc. (NYSE: CRL) launches the Endosafe® Nexus 200™, expanding its robust endotoxin testing portfolio. The Nexus 200 is the next evolution of Charles
Maple Heights Behavioral Health Hosts Ceremony to Celebrate Grand Opening
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced its newest operating joint venture hospital, Maple Heights Behavioral Health, located in Fort Wayne, Indiana, and held a ribbon-tying
LivaNova to Present Scientific Data at American Epilepsy Society 2022 Annual Meeting
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced its participation in the American Epilepsy Society (AES) 2022 Annual Meeting, taking place
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc